Page last updated: 2024-11-05

troglitazone and Fetal Growth Restriction

troglitazone has been researched along with Fetal Growth Restriction in 2 studies

Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Lane, SL1
Doyle, AS1
Bales, ES1
Houck, JA1
Lorca, RA1
Moore, LG1
Julian, CG1
Ruebner, M1
Langbein, M1
Strissel, PL1
Henke, C1
Schmidt, D1
Goecke, TW1
Faschingbauer, F1
Schild, RL1
Beckmann, MW1
Strick, R1

Other Studies

2 other studies available for troglitazone and Fetal Growth Restriction

ArticleYear
Peroxisome proliferator-activated receptor gamma blunts endothelin-1-mediated contraction of the uterine artery in a murine model of high-altitude pregnancy.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2020, Volume: 34, Issue:3

    Topics: Animals; Disease Models, Animal; Endothelin-1; Female; Fetal Growth Retardation; Hypoxia; Immunohist

2020
Regulation of the human endogenous retroviral Syncytin-1 and cell-cell fusion by the nuclear hormone receptors PPARγ/RXRα in placentogenesis.
    Journal of cellular biochemistry, 2012, Volume: 113, Issue:7

    Topics: Alitretinoin; Cell Fusion; Cell Line; Chromans; Cyclic AMP-Dependent Protein Kinases; Endogenous Ret

2012